Generation and validation of human monocyte-derived microglia (MDMi); a Sygnature Discovery screening platform for identifying novel anti-neuroinflammatory drugs

At Sygnature Discovery, we have recently validated the methodology to generate MDMi, an in vitro human cell model to allow the study of anti-neuroinflammatory drugs.


To overcome some of the limitations of primary microglia (limited cell number and restricted life-span in vitro), Sygnature Discovery has validated the generation of MDMi from human monocytes. MDMi shows consistent phenotypic characteristics with primary microglia, as well as expected functionality with P2X7 receptor-mediated calcium signalling and phagocytosis. MDMi shows potential as a microglia model for identifying and characterising novel anti-neuroinflammatory drugs and assisting in the in vitro to in vivo translation.

Download Poster

Poster download form with organisation field
Invalid email address provided.
Please only use your business email address.